Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 6/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.44 |
| ▸ | HRH2 | P25021 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL851414 | 0.94 | CCNC (0.50) | CCNCCDK8KCNA5DRD2SIGMAR1 | |
| SCHEMBL851790 | 0.87 | SIGMAR1 (0.47) | CCNCCDK8KCNA5SIGMAR1SCN9A | |
| SCHEMBL851830 | 0.85 | ST14 (0.54) | CCNCCDK8DRD2SCN9APRKAA2 | |
| SCHEMBL851914 | 0.84 | PRSS1 (0.50) | CCNCCDK8DRD2SCN9APRKAA2 | |
| SCHEMBL851120 | 0.83 | PRKAA2 (0.47) | CCNCCDK8KCNA5PRKAA2 | |
| SCHEMBL852002 | 0.80 | F2 (0.46) | CCNCCDK8DRD2SCN9APRKAA2 | |
| SCHEMBL851458 | 0.80 | GPR119 (0.55) | CCNCCDK8KCNA5SCN9ACYP11B2 | |
| SCHEMBL851247 | 0.80 | F2 (0.46) | CCNCCDK8DRD2SCN9APRKAA2 | |
| SCHEMBL1714545 | 0.80 | DRD2 (0.56) | DRD2HRH2HRH1HRH3 | |
| SCHEMBL850954 | 0.80 | ALDH1A1 (0.47) | CCNCCDK8SCN9APRKAA2HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2014-07-17 | — | — | US | disclosed |
| US-8722930-B2 | Protease inhibitors | ORION CORPORATION (FI) | 2014-05-13 | — | — | US | disclosed |
| US-20120136002-A1 | PROTEASE INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-05-31 | — | — | US | disclosed |
| EP-2432556-A1 | PROTEASE INHIBITORS | Orion Corporation (FI) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133748-A1 | PROTEASE INHIBITORS | ORION CORPORATION (FI) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200225-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | CCNC 2619/4885CDK8 2241/4885KCNA5 2664/4885 |
| US-20120136002-A1 | PROTEASE INHIBITORS | SERPINB1, TMPRSS15, PRSS1 | CCNC 2619/4885CDK8 2241/4885KCNA5 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.